in the news

EXECUTIVE INTERVIEW – Emergent CDMO: A Molecule-to-Market Partner for Complex Biologics

For nearly 25 years, Emergent has developed, manufactured, and delivered their own innovative vaccines and biotherapeutic products to combat public health threats and infectious diseases, thereby building a strong foundation of technical expertise in working with complex molecules and delivering them to the market.

Drawing on this fundamental experience, its CDMO business has supported the development and manufacturing of over 40 commercial and more than 100 clinical biologic programs for their biopharma partners.

Drug Development & Delivery recently interviewed Bill Hartzel, who joined the company in March 2022 as Senior Vice President and Head of CDMO Business, to discuss the company’s plans for current and future CDMO operations and client partnership opportunities.

Read Article


Vaxart AGREEMENT for Experimental Oral Vaccine Candidate for Coronavirus Disease

GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered...


Emergent Announces Additions to Leadership Team

Emergent is pleased to announce the addition of two senior leaders to its  CDMO and Quality & Compliance organizations.


Utilizing Expertise & Experience for Successful Downstream Processing

Successful downstream processing provides isolation of the molecule of interest from extraneous constituents before formulation,...